Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overweight and/or Obesity Clear all
Completed Not applicable Interventional Accepts healthy volunteers

DIETFITS Study (Diet Intervention Examining the Factors Interacting With Treatment Success

NCT01826591
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Low-Carbohydrate Diet, Low-Fat Diet, Mobile App
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 11, 2026, 1:58 AM EDT
Completed No phase listed Observational

BCRL Prevention Pilot

NCT01166672
View directory record Official record
Conditions
Obesity, Breast Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086
View directory record Official record
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Active, not recruiting Phase 3 Interventional

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422
View directory record Official record
Conditions
Hypertension
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Covina, California • Northridge, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

NCT05963594
View directory record Official record
Conditions
Dietary Supplement
Interventions
Oligomalt, maltodextrin
Dietary Supplement
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 11, 2026, 1:58 AM EDT
Not listed Not applicable Interventional

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

NCT03058029
View directory record Official record
Conditions
Overweight, Diabetes, PreDiabetes, Obesity
Interventions
Gelesis200, Placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Early Phase 1 Interventional

Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer

NCT01793948
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
metformin hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Anna Maria Storniolo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal

NCT01402674
View directory record Official record
Conditions
Obesity, Phentermine Withdrawal
Interventions
Abrupt cessation of phentermine pharmacotherapy
Drug
Lead sponsor
Center for Weight Management, California
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Roseville, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Jun 11, 2026, 1:58 AM EDT
Active, not recruiting Phase 1 Interventional

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

NCT07226778
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Maridebart Cafraglutide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions
Maridebart Cafraglutide, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093
View directory record Official record
Conditions
Obesity, Overweight, Chronic Low Back Pain (CLBP)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Postprandial Nutrient Homeostasis Before and After Weight Loss Induced by Low-calorie Diet or RYGB

NCT03091725
View directory record Official record
Conditions
Obesity
Interventions
Roux-en-Y gastric bypass surgery, Low-calorie diet
Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

NCT06712836
View directory record Official record
Conditions
Obesity, Overweight or Obesity
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Anaheim, California • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

NCT02651688
View directory record Official record
Conditions
Acquired Hypogonadotropic Hypogonadism, Obesity
Interventions
Placebo, Enclomiphene
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Albany, New York • Garden City, New York • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Ethambutol Drug Concentrations

NCT01048697
View directory record Official record
Conditions
Obesity, Tuberculosis
Interventions
Ethambutol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

NCT03574597
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
17,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
205
States / cities
Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Jun 11, 2026, 1:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women

NCT00072917
View directory record Official record
Conditions
Obesity, Thinness, Weight Gain
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2010 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

NCT01062165
View directory record Official record
Conditions
Obesity, Fungal Infection
Interventions
Caspofungin
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y

NCT02048501
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Resting Metabolic Rate (RMR), Duel-energy x-ray absorptiometry (DEXA), Visual Analog Scale (VAS), Meal Stimulation Test
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jun 11, 2026, 1:58 AM EDT
Completed Phase 1 Interventional

Study of NGM313 in Obese Participants

NCT03298464
View directory record Official record
Conditions
Obese
Interventions
NGM313, Pioglitazone
Biological · Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jun 11, 2026, 1:58 AM EDT
Recruiting Phase 3 Interventional

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Cagrisema, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
99
States / cities
Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 1:58 AM EDT
Completed No phase listed Observational

Variability of Physical Assessments in an Older Population That is Overweight or Obese

NCT05174923
View directory record Official record
Conditions
Obesity, Aging
Interventions
Short Performance Physical Battery (SPPB Test), 30 Second Chair Stand Test (30CST), Hand grip dynamometry
Behavioral
Lead sponsor
Versanis Bio, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jun 11, 2026, 1:58 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Child Health Initiative for Lifelong Eating and Exercise (CHILE)

NCT00428805
View directory record Official record
Conditions
Obesity
Interventions
classroom curriculum, In-service training for Head Start teachers/aides, Training for Head Start food service, Family intervention component, Food source, Health care providers, CHILE Head Start Intervention
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
3 Years to 5 Years
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jun 11, 2026, 1:58 AM EDT